MAP Kinase Interacting Serine (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC – Pipeline Review, H1 2018

MAP Kinase Interacting Serine


MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC – MAP kinase-interacting serine/threonine-protein kinase 1 is an enzyme encoded by the MKNK1 gene. It plays a role in the response to environmental stress and cytokines and regulate translation by phosphorylating EIF4E, thus increasing the affinity of this protein for the 7-methylguanosine-containing mRNA cap.

Click here for sample report @


Major Key Players:

eFFECTOR Therapeutics Inc

Eli Lilly and Co

Oncodesign SA


MAP Kinase Interacting Serine Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide MAP Kinase Interacting Serine    - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for MAP Kinase Interacting Serine   , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 1 and 1 respectively.

MAP Kinase Interacting Serine pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

MAP Kinase Interacting Serine - Competitive Analysis

Key players are making innovative developments in MAP Kinase Interacting Serine industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector


The pipeline guide provides a snapshot of the global therapeutic landscape of MAP Kinase Interacting Serine.

The pipeline guide reviews pipeline therapeutics for MAP Kinase Interacting Serine by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in MAP Kinase Interacting Serine therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates MAP Kinase Interacting Serine therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for MAP Kinase Interacting Serine.


For Detailed Reading Please visit @


About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:


Partner Relations & Marketing Manager

[email protected]

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Posted by on Tuesday March 13 2018, 9:30 AM EDT. All trademarks acknowledged. Filed under World. Comments and Trackbacks are open. Follow responses: RSS 2.0

Leave a Reply

News Categories

Featured Press Releases

Log in